The comparable efficacy and favorable safety profile vs. daily therapy strengthens TransCon hGH’s differentiation as a once-weekly treatment, potentially driving adoption in Turner syndrome and supporting future label expansion. Traders should monitor progress in the Phase 3 HighLiGHts trial as a key catalyst.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 17 $228.06entry
- T+1 · 8mo ago −0.28%α +1.11% · $227.41
- T+5 · 8mo ago −5.49%α −2.84% · $215.54
- T+20 · 7mo ago +5.99%α +1.68% · $241.71
- T+60 · 5mo ago −6.50%α −16.36% · $213.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCon hGH achieved annualized height velocity (9.05 cm/year) comparable to daily somatropin (9.04 cm/year) in children with Turner syndrome, with a similar safety profile and no cases of slipped capital femoral epiphysis. The data support ongoing Phase 3 HighLiGHts trial efforts for potential label expansion into growth hormone sufficiency indications.
Key Facts
- TransCon hGH demonstrated annualized height velocity of 9.05 cm/year (LS mean) at Week 52, vs. 9.04 cm/year for daily somatropin
- Trial included 49 prepubertal children with Turner syndrome aged 1–10 years
- No occurrences of slipped capital femoral epiphysis (SCFE) in TransCon hGH group
- Adverse events were mild to moderate; none led to discontinuation
- Mean weekly dose: 0.22 mg/kg for TransCon hGH vs. 0.29 mg/kg for daily somatropin
- Safety follow-up extended up to 143 weeks with comparable tolerability
- Phase 3 HighLiGHts basket trial is now underway to support label expansion
Financial Impact
Potential for expanded market share in pediatric growth disorders; supports premium pricing and reimbursement positioning for once-weekly TransCon hGH
Risk Factors
- Regulatory approval not guaranteed despite positive Phase 2 data
- Phase 3 trial may not replicate efficacy or safety findings
- Competition from existing and emerging growth hormone therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257185 |
Track record
41 reports on ASND
14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers